47results about How to "Enhance antibody response" patented technology

The present invention relates to a nutritional composition containing protein, fat and carbohydrate; and a. a nucleotide component selected from the group consisting of nucleic acid, nucleic acid derivatives, nucleotides, nucleoside polyphosphates, polynucleotides, nucleosides, ribose, desoxyribose, and dinucleosidpolyphosphates (Np_xN); and b. a non-proteinaceous negatively charged, glycan or glycoconjugate component with a molecular weight between 200 and 20.000 dalton. The present nutritional composition is particularly suited for feeding infants as it mimics the protective effects of human milk, in particular against allergies and infections.

A novel treatment of Alzheimer's disease and other disorders involving protein misfolding or aggregation is provided by enhancing or sustaining an antibody response against predominantly directed against pathological protein aggregates or neo-epitopes present on pathogenic forms of said protein or protein complex. Furthermore, therapeutic methods are also described, wherein ex vivo stimulated antigen-selected peripheral blood lymphocytes are regrafted into the cognate donor.

A carbohydrate peptide conjugate comprising: a carrier comprising a dendrimeric poly-Lysine enabling multiple epitopes to be covalently attached thereto, at least one peptide comprising one T epitope or several identical or different T epitopes, at least one carbohydrate moiety, or a derivative thereof, containing B epitope, provided it is not a sialoside, or several identical or different epitopes. Use of this conjugate for inducing immune response.

The present invention provides for a vector and a gene expression system for producing a soluble pentameric protein complex comprising the HCMV glycoproteins UL128, UL130, UL131, gH and gL or sequence variants thereof, as well as vaccine compositions comprising the same. The present invention further provides for a vaccine composition for use in prophylactically or therapeutically vaccinating against HCMV infections. Also disclosed are methods of producing the inventive vaccine. Furthermore, the present invention pertains to methods of vaccination of humans with the inventive vaccine composition.

This invention pertains to vaccine compositions comprising a mixture of antigen, such as pneumococcal or meningococcal antigen, and interleukin IL-12, which may be adsorbed onto a mineral in suspension. The pneumococcal or meningococcal antigen may be conjugated to a carrier molecule. These vaccine compositions modulate the protective immune response to the antigen.

A method for efficiently generating antibodies immunizes an animal with a target antigen and a B cell expansion agent, such as an anti-CD40 agonist. The antibodies generated from this method are useful as therapeutic agents, diagnostic agents or research reagents in a variety of diseases and conditions.

Isolated and purified chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs, are provided.

The invention provides immunotherapeutic and prophylactic bacteriophage viral-like particle (VLPs) which are useful in the treatment and prevention of human papillomavirus (HPV) infections and related disorders, including cervical cancer and persistent infections associated with HPV. Related compositions (e.g. vaccines), nucleic acid constructs, and therapeutic methods are also provided. VLPs and related compositions of the invention induce high titer antibody responses against HPV L2 and protect against HPV challenge in vivo. VLPs, VLP-containing compositions, and therapeutic methods of the invention induce an immunogenic response against HPV infection, confer immunity against HPV infection, protect against HPV infection, and reduce the likelihood of infection by HPV infection.

The invention discloses a preparation process of an avian influenza virus split vaccine containing an MF59 adjuvant. The preparation process comprises the following steps of: inoculating an R1203 avian influenza virus strain onto a chicken embryo; inoculating viruses and culturing to obtain a virus liquid; inactivating viruses and purifying; cracking; purifying once again; removing bacteria and filtering, and the like. The preparation process has the beneficial effects that: the vaccine prepared from the MF59 adjuvant has high immunogenicity, and can generate higher antibody response; the immunity of children and the old who cannot generate immune response or have low immune response after inoculation of the conventional vaccine can be enhanced; cross immunity can be generated for different influenza virus subtypes; and on the premise of keeping constant immunity, the antigen content can be lowered, the content of foreign proteins capable of causing side reactions is lowered simultaneously, the side reaction of the vaccine is lower, higher safety is achieved, and the risks of virulence returning strength and variation are avoided.

The present invention relates to a glycoconjugate, a composition and vaccine comprising the same and to the use thereof for enhancing the immune response in cancer therapy wherein the induction of a humoral or a cellular immune response is sought. The invention also relates to a diagnosis kit and to a method for the diagnosis of a cancer.

The invention provides a method for producing anti-human C-reaction protein antiserum for sheep. The method comprises the following steps of: (1) preparing an antigen; (2) performing injection for the first time: using the antigen emulsion to inject the sheep, wherein injection parts are soles of feet, inguinal regions, armpits, necks, backs and subcutaneous multipoint injection; (3) performing injection for the second time; (4) performing injection for the third time; (5) performing injection for the fourth time; (6) performing injection for the fifth time; and (7) detecting serum titer: drawing blood from the vein of the sheep after 8-10 days from the injection each time, separating the serum and detecting dual-extending titer. Compared with the prior art, the method for producing the anti-human C-reaction protein antiserum for the sheep, disclosed by the invention, is low in cost, and simple in process; the method not only can stably produce the antibodies, but also is high in antibody producing speed; the antibody level is high, and the dosage of the antigen is small.

The invention belongs to the field of gene engineering, and discloses a preparation method and applications of an anti-pseudorabies virus pig origin monoclonal antibody. The preparation method comprises following steps: positive hybridoma cells capable of realizing stable secretion of anti-pseudorabies virus (PRV) glycoprotein monoclonal antibodies are screened; secretion of the monoclonal antibodies is carried out; enlarge culture is carried out; enrichment, purification, and sequencing are carried out; design of corresponding specific primers is carried out, pig origin modification is carried out, cloning is carried out using a virus gene carrier or a non-virus gene carrier (including plasmid DNA and minicircle DNA), large scale production of different pig origin monoclonal antibodies iscarried out using insect cells or CHO cell fermentation, or the above pig origin monoclonal antibody gene carrier is introduced into pigs; injection, or feeding through nasal feeding and spraying areadopted for neutralization of pseudorabies virus with the anti-pseudorabies virus pig origin monoclonal antibodies, so that passive immunity is adopted for purifying of pseudorabies virus positive pig farms, and preventing and treating of porcine pseudorabies.

The invention provides immunotherapeutic and prophylactic bacteriophage viral-like particle (VLPs) which are useful in the treatment and prevention of human papillomavirus (HPV) infections and related disorders, including cervical cancer and persistent infections associated with HPV. Related compositions (e.g. vaccines), nucleic acid constructs, and therapeutic methods are also provided. VLPs and related compositions of the invention induce high titer antibody responses against HPV L2 and protect against HPV challenge in vivo. VLPs, VLP-containing compositions, and therapeutic methods of the invention induce an immunogenic response against HPV infection, confer immunity against HPV infection, protect against HPV infection, and reduce the likelihood of infection by HPV infection.

The invention provides compounds of formula I: wherein R1-R3, Ra, and Rb have any of the values defined herein, and salts thereof. The compounds have immunomodulatory properties.

This invention relates to the field of vaccination and treatment or prevention diseases. In particular this invention relates to the treatment or prevention of diseases by inducing hapten-specific antibody responses in a vaccinated subject. The invention further provides a method for prevention or treatment of a disease by inducing hapten-specific antibodies in a subject comprising administering into said subject a composition comprising a virus-like particle of an RNA bacteriophage and at least one hapten linked thereto.

An influenza vaccine comprising an influenza hemagglutinin-containing antigen which is subjected to a treatment at a suitable low pH or other suitable conditions to obtain a suitable degree of loss of potency, and the method of making it are provided. The vaccine not only induces an increased cross-reactive immune response and cross protection, but can also induce a strain-specific immune response and protection like current inactivated vaccines. A method of administering influenza vaccines is also provided to induce an increased cross-reactive immune response and cross protection, which is especially suitable for use in emergency situations such as a pandemic.